爱泼斯坦-巴尔病毒抗体升高提示恶性淋巴瘤风险增加——一项前瞻性研究
Increased risk of malignant lymphoma indicated by elevated Epstein-Barr virus antibodies--a prospective study.
作者信息
Lehtinen T, Lumio J, Dillner J, Hakama M, Knekt P, Lehtinen M, Teppo L, Leinikki P
机构信息
Department of Biomedical Sciences, University of Tampere, Finland.
出版信息
Cancer Causes Control. 1993 May;4(3):187-93. doi: 10.1007/BF00051312.
We estimated Epstein-Barr virus (EBV) antibody-associated relative risks (RR) of malignant lymphoma/leukemia within a cohort of 39,000 healthy Finnish adults followed up for 12 years. Antibody analyses to EBV capsid antigen (VCA), early antigen (EA), and nuclear antigens (EBNA, EBNA1, and EBNA2) were based on concomitantly evaluated ELISA techniques. No increased risk was associated with mere EBV seropositivity. However, elevated EBV EA and EBNA antibody levels were associated with a statistically significant excess risk of malignant lymphoma/leukemia (RREA = 3.4, 95 percent confidence interval [CI] = 1.0-11.0; RREBNA = 4.5, CI = 1.2-16.9). These elevated antibody responses may be due either to destruction of neoplastic EBV positive B-cells and/or to activation of latent EBV infection early in the lymphomagenesis.
我们在一个由39000名健康芬兰成年人组成的队列中进行了12年随访，估计了爱泼斯坦-巴尔病毒（EBV）抗体相关的恶性淋巴瘤/白血病相对风险（RR）。针对EBV衣壳抗原（VCA）、早期抗原（EA）和核抗原（EBNA、EBNA1和EBNA2）的抗体分析基于同时评估的酶联免疫吸附测定（ELISA）技术。单纯EBV血清阳性未显示风险增加。然而，EBV EA和EBNA抗体水平升高与恶性淋巴瘤/白血病的统计学显著超额风险相关（RREA = 3.4，95%置信区间[CI] = 1.0 - 11.0；RREBNA = 4.5，CI = 1.2 - 16.9）。这些升高的抗体反应可能是由于肿瘤性EBV阳性B细胞的破坏和/或淋巴瘤发生早期潜伏性EBV感染的激活。
Zotero 插件